文献速递前列腺癌

二甲双胍使用、遗传变异与前列腺癌风险的关系

Association between metformin medication, genetic variation and prostate cancer risk.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-05-18

该病例对照研究纳入1996至2014年前列腺穿刺队列的3481名男性,其中132人(4%)诊断时服用二甲双胍。调整基线特征后,二甲双胍使用与高级别前列腺癌(OR=1.76,95%CI 1.1-2.9,p=0.02)及总体前列腺癌(OR=1.77,95%CI 1.1-2.9,p=0.03)风险升高相关。27个二甲双胍代谢通路候选SNP未见显著交互作用,但全基因组关联研究(GWAS)发现的rs149137006与高级别前列腺癌、rs115071742与总体前列腺癌存在全基因组显著交互。

要点

  • 二甲双胍使用与前列腺癌诊断风险升高相关,而非降低。
  • 二甲双胍代谢通路候选SNP未显著改变该关联。
  • 两个GWAS来源的非编码SNP显示显著交互,需进一步验证。

核心结论

  • 在本队列中,二甲双胍使用与前列腺癌诊断风险升高相关。
  • 二甲双胍代谢通路SNP未显著修饰该关联,但两个GWAS来源SNP有全基因组显著交互。

研究设计与样本

  • 病例对照研究,数据来自1996至2014年前列腺穿刺数据库,共纳入3481名男性。
  • 收集临床数据及胚系DNA,在GWAS基础上定制SNP阵列纳入27个二甲双胍代谢相关SNP。
  • 采用病例对照设计分析二甲双胍与高级别(Grade Group≥2)及总体前列腺癌风险,采用病例-only设计探索SNP交互。

主要发现

  • 3481名男性中132人(4%)诊断时服用二甲双胍。
  • 二甲双胍使用者年龄更大、非白人比例更高、BMI更高、Gleason评分更高、阳性穿刺针数更多。
  • 2061人(59%)诊断为前列腺癌,其中922人(45%)为高级别。
  • 调整基线特征后,二甲双胍使用与高级别前列腺癌风险升高相关(OR=1.76,95%CI 1.1-2.9,p=0.02)。
  • 二甲双胍使用与总体前列腺癌风险升高相关(OR=1.77,95%CI 1.1-2.9,p=0.03)。

关键数值与推荐

  • 27个二甲双胍代谢通路候选SNP均未与二甲双胍-癌症关联存在显著交互。
  • GWAS SNP rs149137006与二甲双胍对高级别前列腺癌的交互达全基因组显著。
  • GWAS SNP rs115071742与二甲双胍对总体前列腺癌的交互达全基因组显著。
  • rs149137006为内含子SNP,rs115071742为基因间SNP,在前列腺癌化学预防中的作用大多未明确。

临床怎么用

  • 对于服用二甲双胍的男性,应知晓其前列腺癌诊断风险可能升高,但需结合遗传背景综合评估。
  • 目前不推荐基于二甲双胍使用或上述SNP改变前列腺癌筛查或化学预防策略。
  • 相关遗传交互作用需在前瞻性队列中进一步验证。

局限性

  • 研究为单中心穿刺队列的病例对照设计,可能存在选择偏倚。
  • 二甲双胍使用者仅132人(4%),样本量有限。
  • 两个交互SNP功能未明,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between metformin use and prostate cancer risk remains controversial. Genetic variation in metformin metabolism pathways appears to modify metformin glycemic control and the protective association with some cancers. However, no studies to date have examined this pharmacogenetic interaction and prostate cancer chemoprevention. METHODS: Clinical data and germline DNA were collected from our prostate biopsy database between 1996 and 2014. In addition to a genome-wide association study (GWAS), 27 single nucleotide polymorphisms (SNPs) implicated in metformin metabolism were included on a custom SNP array. Associations between metformin use and risk of high-grade (Grade Group ≥ 2) and overall prostate cancer were explored using a case-control design. Interaction between the candidate/GWAS SNPs and the metformin-cancer association was explored using a case-only design. RESULTS: Among 3481 men, 132 (4%) were taking metformin at diagnosis. Metformin users were older, more likely non-Caucasian, and had higher body mass index, Gleason score, and number of positive cores. Overall, 2061 (59%) were diagnosed with prostate cancer, of which 922 (45%) were high-grade. After adjusting for baseline characteristics, metformin use was associated with higher risk of high-grade prostate cancer (OR = 1.76, 95% CI 1.1-2.9, p = 0.02) and overall prostate cancer (OR = 1.77, 95% CI 1.1-2.9, p = 0.03). None of the 27 candidate SNPs in metformin metabolic pathways had significant interaction with the metformin-cancer association. Among the GWAS SNPs, one SNP (rs149137006) had genome-wide significant interaction with metformin for high-grade prostate cancer, and another, rs115071742, for overall prostate cancer. They were intronic and intergenic SNPs, respectively, with largely uncharacterized roles in prostate cancer chemoprevention. CONCLUSIONS: In our cohort, metformin use was associated with increased risk of being diagnosed with prostate cancer. While SNPs involved in metformin metabolism did not have modifying effects on the association with disease risk, one intronic and one intergenic SNP from the GWAS study did, and these require further study.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lee MJ, Jayalath VH, Xu W, et al. Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer Prostatic Dis. 2020. PMID: 32424261. doi:10.1038/s41391-020-0238-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。